http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Birth Weight and the Development of Functional Gastrointestinal Disorders in Infants
Maria Elisabetta Baldassarre,Antonio Di Mauro,Silvia Salvatore,Silvio Tafuri,Francesco Paolo Bianchi,Enzo Dattoli,Lucia Morando,Licia Pensabene,Fabio Meneghin,Dario Dilillo,Valentina Mancini,Valentina 대한소아소화기영양학회 2020 Pediatric gastroenterology, hepatology & nutrition Vol.23 No.4
Purpose: To assess the association between birth weight and the development of functional gastrointestinal disorders (FGIDs) in the first year of life. Methods: This is a secondary analysis of a prospective cohort multicenter study including neonates, consecutively enrolled at birth, and followed up for one year. At birth all infants were classified by birth weight as extremely low (ELBW), very low, or low when <1,000, <1,500, and <2,500 g, respectively, and by birth weight for gestational age as appropriate (AGA, weight in the 10–90th percentile), small (SGA, weight <10th percentile), and large (LGA, weight >90th percentile) for gestational age. FGIDs were classified according to the Rome III criteria and assessed at 1, 3, 6, and 12 months of life. Results: Among 1,152 newborns enrolled, 934 (81.1%) completed the study: 302 (32.3%) were preterm, 35 (3.7%) were ELBW, 104 (11.1%) were SGA, 782 (83.7%) were AGA, and 48 (5.1%) were LGA infants. Overall, throughout the first year of life, 718 (76.9%) reported at least one FGID. The proportion of infants presenting with at least one FGID was significantly higher in ELBW (97%) compared to LBW (74%) (p=0.01) and in LGA (85.4%) and SGA (85.6%) compared to AGA (75.2%) (p=0.0001). On multivariate analysis, SGA was significantly associated with infantile colic. Conclusion: We observed an increased risk of FGIDs in ELBW, SGA, and LGA neonates. Our results suggest that prenatal factors determining birth weight may influence the development of FGIDs in infants. Understanding the role of all potential risk factors may provide new insights and targeted approaches for FGIDs.
Birth Weight and the Development of Functional Gastrointestinal Disorders in Infants
Baldassarre, Maria Elisabetta,Di Mauro, Antonio,Salvatore, Silvia,Tafuri, Silvio,Bianchi, Francesco Paolo,Dattoli, Enzo,Morando, Lucia,Pensabene, Licia,Meneghin, Fabio,Dilillo, Dario,Mancini, Valentin The Korean Society of Pediatric Gastroenterology 2020 Pediatric gastroenterology, hepatology & nutrition Vol.23 No.4
Purpose: To assess the association between birth weight and the development of functional gastrointestinal disorders (FGIDs) in the first year of life. Methods: This is a secondary analysis of a prospective cohort multicenter study including neonates, consecutively enrolled at birth, and followed up for one year. At birth all infants were classified by birth weight as extremely low (ELBW), very low, or low when <1,000, <1,500, and <2,500 g, respectively, and by birth weight for gestational age as appropriate (AGA, weight in the 10-90th percentile), small (SGA, weight <10th percentile), and large (LGA, weight >90th percentile) for gestational age. FGIDs were classified according to the Rome III criteria and assessed at 1, 3, 6, and 12 months of life. Results: Among 1,152 newborns enrolled, 934 (81.1%) completed the study: 302 (32.3%) were preterm, 35 (3.7%) were ELBW, 104 (11.1%) were SGA, 782 (83.7%) were AGA, and 48 (5.1%) were LGA infants. Overall, throughout the first year of life, 718 (76.9%) reported at least one FGID. The proportion of infants presenting with at least one FGID was significantly higher in ELBW (97%) compared to LBW (74%) (p=0.01) and in LGA (85.4%) and SGA (85.6%) compared to AGA (75.2%) (p=0.0001). On multivariate analysis, SGA was significantly associated with infantile colic. Conclusion: We observed an increased risk of FGIDs in ELBW, SGA, and LGA neonates. Our results suggest that prenatal factors determining birth weight may influence the development of FGIDs in infants. Understanding the role of all potential risk factors may provide new insights and targeted approaches for FGIDs.
Barlesi, F.,Scherpereel, A.,Gorbunova, V.,Gervais, R.,Vikströ,m, A.,Chouaid, C.,Chella, A.,Kim, J. H.,Ahn, M. J.,Reck, M.,Pazzola, A.,Kim, H. T.,Aerts, J. G,Morando, C.,Loundou, A.,Groen, H. J. M. Oxford University Press 2014 Annals of oncology Vol.25 No.5
<P>The randomized, phase III AVAPERL trial evaluated the safety and efficacy of bevacizumab maintenance with or without pemetrexed in nonsquamous non–small cell lung cancer (nsNSCLC). Progression-free survival (PFS) was significantly prolonged with bevacizumab–pemetrexed. At a median follow-up of 14.8 months, OS events occurred in 58% of all patients. OS was numerically longer with bevacizumab–pemetrexed versus bevacizumab when measured from randomization (17.1 versus 13.2 months, HR, 0.87 [0.63–1.21]; P=0.29). Second-line therapy was administered in 77% and 70% of patients in the bevacizumab and bevacizumab–pemetrexed arms, respectively.</P>